Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression

Current Pharmaceutical Design

Volumn 19, Issue 10, 2013, Pages 1898-1922

  Serafini, Gianluca ^a   Pompili, Maurizio ^a   Innamorati, Marco ^a   Dwivedi, Yogesh ^b   Brahmachari, Goutam ^c   Girardi, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c VISVA BHARATI UNIVERSITY   (India)

Author keywords

Antidepressant drugs; Glutamatergic abnormalities; Major depression; NMDA receptors

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; 4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; AMANTADINE; BIFEMELANE; CITALOPRAM; CLOZAPINE; CYCLOSERINE; DIZOCILPINE; ESCITALOPRAM; FLUOXETINE; GLUTAMIC ACID; GLYCINE; IMIPRAMINE; KETAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERAMEXANE; NEUROTRANSMITTER; PAROXETINE; PHENCYCLIDINE; PRAZOSIN; PSYCHEDELIC AGENT; RILUZOLE; RITANSERIN; SERTRALINE; SULPIRIDE; TRAXOPRODIL; UNINDEXED DRUG; ZACOPRIDE;

ANTIDEPRESSANT ACTIVITY; ARTICLE; CLINICAL TRIAL (TOPIC); COGNITION; DATA BASE; HUMAN; MAJOR DEPRESSION; NERVOUS SYSTEM DEVELOPMENT; NEUROIMAGING; NONHUMAN; POSTSYNAPTIC DENSITY; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; STEM CELL; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; GLUTAMATES; HUMANS; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION;

EID: 84876736749     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990293     Document Type: Article

References (151)

1. Szakacs R, Janka Z, Kalman J. The "blue" side of glutamatergic neurotransmission: NMDA receptor antagonists as possible novel therapeutics for major depression. Neuropsychopharmacol Hung 2012; 14: 29-40.
2. Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 2009; 30: 563-9.
3. Tohen M, Hennen J, Zarate CM Jr, et al. Two-year syndromal and functional recovery in 219 cases of first episode major affective disorder with psychotic features. Am J Psychiatry 2000; 157: 220-8.
4. Pompili M, Innamorati M, Rihmer Z, et al. Cyclothymicdepressive-anxious temperament pattern is related to suicide risk in 346 patients with major mood disorders. J Affect Disord 2012; 136: 405-11.
5. Pompili M, Rihmer Z, Akiskal H, et al. Temperaments mediate suicide risk and psychopathology among patients with bipolar disorders. Compr Psychiatry 2012; 53: 280-5.
6. Serafini G, Pompili M, Innamorati M, et al. The role of microRNAs in synaptic plasticity, major affective disorders and suicidal behavior. Neurosci Res 2012; 73: 179-90.
7. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747-57.
8. McIntyre RS, Rosenbluth M, Ramasubbu R, et al. Managing medical and psychiatric comorbidity in individuals with major depressi ve disorder and bipolar disorder. Ann Clin Psychiatry 2012; 24: 163-9.
9. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40.
10. Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry 2006; 163: 1161-72.
11. Racagni G, Popoli M. Cellular and molecular mechanisms in the long-term action of antidepressants. Dialog Clin Neurosci 2008; 10: 385-400.
12. Belmaker RH. The future of depression psychopharmacology. CNS Spectr 2008; 13: 682-7.
13. Manji HK, Quiroz JA, Sporn J, et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 2003; 53: 707-42.
14. Maeng S, Zarate CA Jr. The role of glutamate in mood disorders: Results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep 2007; 9: 467-74.
15. Müller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 2007; 12: 988-1000.
16. Müller N, Myint AM, Schwarz MJ. The impact of neuroimmune dysregulation on neuroprotection and neurotoxicity in psychiatric disorders-relation to drug treatment. Dialogues Clin Neurosci 2009; 11: 319-32.
17. Maeng S, Zarate Jr. CA, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008; 63: 349-52.
18. Sanderson TM, Collingridge GL, Fitzjohn SM. Differential trafficking of AMPA receptors following activation of NMDA receptors and mGluRs. Mol Brain 2011; 4: 30.
19. Unoki T, Matsuda S, Kakegawa W, et al. NMDA receptormediated PIP5K activation to produce PI(4,5)Pβ is essential for AMPA receptor endocytosis during LTD. Neuron 2012; 73: 135-48.
20. Dyba M, Siwek A, Poleszak E, Pilc A, Nowak G. Lack of NMDA-AMPA interaction in antidepressant-like effect of CGP 37849, an antagonist of NMDA receptor, in the forced swim test. J Neural Transm 2008; 115: 1519-20.
21. Wenthold RJ, Roche KW. The organization and regulation of non-NMDA receptors in neurons. In: Ottersen OP, Langmoen IA, Gjerstad L. Eds. Progress in Brain Research, Vol. 116, The Glutamate Synapse as a Therapeutical Target: Molecular Organization and Pathology of the Glutamate Synapse. Amsterdam: Elsevier 1998; pp. 133-52.
22. Molnar E, Isaac JT. Developmental and activity dependent regulation of ionotropic glutamate receptors at synapses. ScientificWorld-Journal 2002; 2: 27-47.
23. Bekkers JM, Stevens CF. NMDA and non-NMDA receptors are co-localized at individual excitatory synapses in cultured rat hippocampus. Nature 1989; 341: 230-3.
24. Shors TJ, Seib TB, Levine S, Thompson RF. Inescapable versus escapable shock modulates long-term potentiation in the rat hippocampus. Science 1989; 244: 224-6.
25. Harris EW, Ganong AH, Cotman CW. Long-term potentiation in the hippocampus involves activation of N-methyl-D-aspartate receptors. Brain Res 1984 3; 323: 132-7.
26. Morris RG, Anderson E, Lynch GS, Baudry M. Selective impairment of learning and blockade of long-term potentiation by an Nmethyl-D-aspartate receptor antagonist, AP5. Nature 1986; 319: 774-6.
27. Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990; 185: 1-10.
28. Pittenger C, Sanacora G, Krystal JH. The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets 2007; 6: 101-15.
29. Mineur YS, Picciotto MR, Sanacora G. Antidepressant like effects of ceftriaxone in male C57BL 6J mice. Biol Psychiatry 2007; 61: 250-2.
30. Molina-Hernandez M, Tellez-Alcantara NP, Perez-Garcia J, Olivera-Lopez JI, Jaramillo-Jaimes MT. Antidepressantlike actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 380-6.
31. Peineau S, Taghibiglou C, Bradley C, et al. LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 2007; 53: 703-17.
32. Bradley CA, Peineau S, Taghibiglou C, et al. A pivotal role of GSK-3 in synaptic plasticity. Front Mol Neurosci 2012; 5: 13.
33. Yaka R, He DY, Phamluong K, Ron D. Pituitary adenylate cyclaseactivating polypeptide (PACAP(1-38) enhances N-methyl-Daspartate receptor function and brain-derived neurotrophic factor expression via RACK1. J Biol Chem 2003; 278: 9630-8.
34. Macdonald DS, Weerapura M, Beazely MA, et al. Modulation of NMDA receptors by pituitary adenylate cyclase activating peptide in CA1 neurons requires G alpha q, protein kinase C, and activation of Src. J Neurosci 2005; 25: 11374-84.
35. Bhattacharyya S, Biou V, Xu W, Schlüter O, Malenka RC. A critical role for PSD-95/AKAP interactions in endocytosis of synaptic AMPA receptors. Nat Neurosci 2009; 12: 172-81.
36. Corcoran KA, Donnan MD, Tronson NC, et al. NMDA receptors in retrosplenial cortex are necessary for retrieval of recent and remote context fear memory. J Neurosci 2011; 31: 11655-9.
37. Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate ion channels. Pharmacol Rev 1999; 51: 7-61.
38. Campbell S, Macqueen G. The role of hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci 2004; 29: 417-26.
39. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977; 229: 327-36.
40. Papp M, Moryl E. New evidence for the antidepressant activity of MK-801, a non-competitive antagonist of NMDA receptors. Pol J Pharmacol 1993; 45: 549-53.
41. Padovan CM, Guimarães FS. Antidepressant-like effects of NMDA-receptor antagonist injected into the dorsal hippocampus of rats. Pharmacol Biochem Behav 2004; 77: 15-19.
42. Papp M, Moryl E. Antidepressant-like effects of 1-aminocyclopropanecarbxylic acid and D-cycloserine in an animal model of depression. Eur J Pharmacol 1996; 316: 145-51.
43. Lopes T, Neubauer P, Boje KM. Chronic administration of NMDA glycine partial agonists induces tolerance in the Porsolt swim test. Pharmacol Biochem Behav 1997; 58: 1059-64.
44. Crane GE. Cycloserine as an antidepressant agent. Am J Psychiatry 1959; 115: 1025-6.
45. Crane GE. The psychotropic effects of cycloserine: a new use for an antibiotic. Compr Psychiatry 1961; 2: 51-9.
46. Heresco-Levy U, Javitt DC, Gelfin Y, et al. Controlled trial of Dcycloserine adjuvant therapy for treatment-resistant major depressive disorder. J Affect Disord 2006; 93: 239-43.
47. Richter-Levin G, Maroun M. Stress and amygdala suppression of metaplasticity in the medial prefrontal cortex. Cereb Cortex 2010; 20: 2433-41.
48. Szakacs R, Weiczner R, Mihaly A, Krisztin-Peva B, Zador Z, Zador E. Non-competitive NMDA receptor antagonists moderate seizure-induced c-fos expression in the rat cerebral cortex. Brain Res Bull 2003; 59: 485-93.
49. Maj J, Rogoz Z, Skuza G, Wedzony K. The synergistic effect of fluoxetine on the locomotor hyperactivity induced by MK-801, a non-competitive NMDA receptor antagonist. J Neural Transm 1996; 103: 131-46.
50. Redmond AM, Kelly JP, Leonard BE. Behavioural and neurochemical effects of dizocilpine in the olfactory bulbectomized rat model of depression. Pharmacol Biochem Behav 1997; 58: 355-9.
51. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351-4.
52. Koike H, Iijima M, Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 2011; 224: 107-11.
53. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329: 959-64.
54. Chaturvedi HK, Chandra D, Bapna JS. Interaction between Nmethyl-D-aspartate receptor antagonists and imipramine in shockinduced depression. Indian J Exp Biol 1999; 37: 952-8.
55. Yilmaz A, Schulz D, Aksoy A, Canbeyli R. Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav 2002; 71: 341-4.
56. Kudoh A, Takahira Y, Katagai H, Takazawa T. Small-dose ketamine improves the postoperative state of depressed patients. Anesth Analg 2002; 95: 114-8, table of contents.
57. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006b; 63: 856-64.
58. Ibrahim L, Diazgranados N, Luckenbaugh DA, et al. Rapid decrease in depressive symptoms with an N-methyl-D-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1155-9.
59. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized addon trial of an Nmethyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010; 67: 793-802.
60. Mathew SJ, Murrough JW, Aan Het Rot M, et al. Riluzole for relapse prevention following intravenous ketamine in treatmentresistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol 2009; 17: 1-12.
61. Ostroff R, Gonzales M, Sanacora G. Antidepressant effect of ketamine during ECT. Am J Psychiatry 2005; 162: 1385-6.
62. Liebrenz M, Borgeat A, Lesinger R, Stohler R. Intravenous ketamine therapy in a patient with a treatment-resistant major depression. Swiss Med Wkly 2007; 137: 234-46.
63. Liebrenz M, Stohler R, Borgeat A. Repeated intravenous ketamine therapy in a patient with a treatment-resistant major depression. World J Biol Psychiatry 2009; 10: 640-3.
64. Stefanczyk-Sapieha L, Oneschuk D, Demas M. Intravenous ketamine "burst" for refractory depression in a patient with advanced cancer. J Palliat Med 2008; 11: 1268-71.
65. Phelps LE, Brutsche N, Moral JR, Luckenbaugh DA, Manji HK, Zarate CA Jr. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry 2009; 65: 181-4.
66. Salvadore G, Cornwell BR, Colon-Rosario V, et al. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 2009; 65: 289-95.
67. Autry AE, Adachi M, Nosyreva E, et al. NMDA receptor blockade at rest triggers rapid behavioral antidepressant responses. Nature 2011; 475: 91-5.
68. Machado-Vieira R, Yuan P, Brutsche N, et al. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry. 2009; 70: 1662-6.
69. Tordera RM, Totterdell S, Wojcik SM, et al. Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1). Eur J Neurosci 2007; 25: 281-90.
70. Farley S, Dumas S, El Mestikawy S, Giros B. Increased expression of the Vesicular Glutamate Transporter-1 (VGLUT1) in the prefrontal cortex correlates with differential vulnerability to chronic stress in various mouse strains: effects of fluoxetine and MK-801. Neuropharmacology 2012; 62: 503-17.
71. Garcia LS, Comim CM, Valvassori SS, et al. Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 450-5.
72. Sinner B, Graf BM. Ketamine. Handb Exp Pharmacol 2008; 182: 313-33.
73. Paul R, Schaaff N, Padberg F, Möller HJ, Frodl T. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases. World J Biol Psychiatry 2009; 10: 241-4.
74. Paslakis G, Gilles M, Meyer-Lindenberg A, Deuschle M. Oral administration of the NMDA receptor antagonist S-ketamine as add-on therapy of depression: a case series. Pharmacopsychiatry 2010; 43: 33-5.
75. Williams K. Ifenprodil discriminates subtypes of the N-methyl-Daspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol 1993; 44: 851-9.
76. Gallagher MJ, Huang H, Pritchett DB, Lynch DR. Interactions between ifenprodil and the NR2B subunit of the N-methyl-Daspartate receptor. J Biol Chem 1996; 271: 9603-11.
77. Chenard BL, Menniti FS. Antagonists selective for NMDA receptors containing the NR2B subunit. Curr Pharm Des 1999; 5: 381-404.
78. Chizh BA, Headley PM, Tzschentke TM. NMDA receptor antagonists as analgesics: focus on the NR2B subtype. Trends Pharmacol Sci 2001; 22: 636-42.
79. Borza I, Domány G. NR2B selective NMDA antagonists: the evolution of the ifenprodil-type pharmacophore. Curr Top Med Chem 2006; 6: 687-95.
80. Hashimoto K, London ED. Further characterization of [3H] ifenprodil binding to sigma receptors in rat brain. Eur J Pharmacol 1993; 236: 159-163.
81. Hashimoto K, London ED. Interactions of erythro-ifenprodil, threoifenprodil, erythro-iodoifenprodil, and eliprodil with subtypes of sigma receptors. Eur J Pharmacol 1995; 273: 307-10.
82. Hashimoto K, Mantione CR, Spada MR, Neumeyer JL, London ED. Further characterization of [3H]ifenprodil binding in rat brain. Eur J Pharmacol 1994; 266: 67-77.
83. Hashimoto K. Comments to "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder". J Clin Psychopharmacol 2009a; 29: 411-2.
84. Coughenour LA, Barr BM. Use of trifluoroperazine isolates a [3H]ifenprodil binding site in rat brain membranes with the pharmacology of the voltage-independent idenprodil site on N methyl-D-aspartate receptors containing NR2B subunits. J Pharmacol Exp Ther 2001; 296: 150-9.
85. Gill R, Alanine A, Bourson A, et al. Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methylbenzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-Daspartate antagonist. J Pharmacol Exp Ther 2002; 302: 940-8.
86. Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989; 244: 1360-2.
87. Hashimoto K, Tomitaka S, Bi Y, Narita N, Minabe Y, Iyo M. Rolipram, a selective phosphodiesterase type-IV inhibitor, prevents induction of heat shock protein HSP-70 and hsp-70 mRNA in rat retrosplenial cortex by the NMDA receptor antagonist dizocilpine. Eur J Neurosci 1997; 9: 1891-901.
88. Tomitaka S, Hashimoto K, Narita N, Sakamoto A, Minabe Y, Tamura A. Memantine induces heat shock protein HSP70 in the posterior cingulate cortex, retrosplenial cortex and dentate gyrus of rat brain. Brain Res 1996; 740: 1-5.
89. Okamura N, Hashimoto K, Shimizu E, et al. Protective effect of LY379268, a selective group II metabotropic glutamate receptor agonist, on dizocilpine-induced neuropathological changes in rat retrosplenial cortex. Brain Res 2003; 992: 114-9.
90. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-Daspartate antagonist, CP-101,606, in patients with treatmentrefractory major depressive disorder. J Clin Psychopharmacol 2008; 28: 631-7.
91. Mott DD, Doherty JJ, Zhang S, et al. Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat Neurosci 1998; 1: 659-67.
92. Kemp JA, McKernan RM. NMDA receptor pathways as drug targets. Nat Neurosci 2002; 5 (Suppl): 1039-42.
93. Boyce-Rustay JM, Holmes A. Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic-and antidepressant-like effects in mice. Neuropsychopharmacology 2006; 31: 2405-14.
94. Hashimoto K. Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationship. Cent Nerv Syst Agents Med Chem 2009c; 9: 197-204.
95. Hayashi T, Stahl SM. The sigma-1 receptor and its role in the treatment of mood disorders. Drugs Future 2009; 34: 137-46.
96. Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Human Psychopharmacol 2010; 25: 193-200.
97. Ishikawa M, Hashimoto K. The role of sigma-1 receptors in the pathophysiology of neuropsychiatric diseases. J Receptor Ligand Channel Res 2010; 3: 25-36.
98. Matrisciano F, Tueting P, Maccari S, Nicoletti F, Guidotti A. Pharmacological activation of group-II metabotropic glutamate re ceptors corrects a schizophrenia-like phenotype induced by prenatal stress in mice. Neuropsychopharmacology 2012; 37: 929-38.
99. Parsons CG, Panchenko VA, Pinchenko VO, Tsyndrenko AY, Krishtal OA. Comparative patch clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine. Eur J Neurosci 1996; 8: 446-54.
100. Danysz W, Parsons CG, Komhuber J, Schmidt WJ, Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies. Neurosci Biobehav Rev 1997; 21: 455-68.
101. Zarate CA, Quiroz J, Payne J, Manji HK. Modulators of the glutamatergic system: Implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull 2002; 36: 35-83.
102. Huber TJ, Dietrich DE, Emrich HM. Possible use of amantadine in depression. Pharmacopsychiatry 1999; 32: 47-55.
103. Dietrich DE, Bode L, Spannhuth CW, et al. Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial. Bipolar Disord 2000; 2: 65-70.
104. Rogóz Z, Skuza G, Maj J, Danysz W. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swim test in rats. Neuropharmacology 2002; 42: 1024-30.
105. Rogóz Z, Skuza G, Kućmider M, Wójcikowski J, Kot M, Daniel WA. Synergistic effect of imipramine and amantadine in the forced swimming test in rats. Behavioral and pharmacokinetic studies. Pol J Pharmacol 2004; 56: 179-85.
106. Stryjer R, Strous RD, Shaked G, et al. Amantadine as augmentation therapy in the management of treatment-resistant depression. Int Clin Psychopharmacol 2003; 18: 93-6.
107. Moryl E, Danysz W, Quack G. Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol 1993; 72: 394-7.
108. Sani G, Serra G, Kotzalidis GD, et al. The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence. CNS Drugs 2012; 26: 663-90.
109. Ferguson JM, Shingleton RN. An open-label, flexible-dose study of memantine in major depressive disorder. Clin Neuropharmacol 2007; 30: 136-44.
110. Kollmar R, Markovic K, Thürauf N, Schmitt H, Kornhuber J. Ketamine followed by memantine for the treatment of major depression. Aust NZ J Psychiatry 2008; 42: 170.
111. Koukopoulos A, Reginaldi D, Serra G, Koukopoulos A, Sani G, Serra G. Antimanic and mood-stabilizing effect of memantine as an augmenting agent in treatment-resistant bipolar disorder. Bipolar Disord 2010; 12: 348-9.
112. Zarate CA Jr, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006a; 163: 153-5.
113. Muhonen LH, Lonnqvist J, Juva K, Alho H. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry 2008; 69: 392-9.
114. Tsai GE. Searching for rational anti-N-methyl-D-aspartate treatment for depression. Arch Gen Psychiatry 2007; 64: 1099-100.
115. Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate-tosevere Alzheimer's disease. N Eng J Med 2003; 348: 1333-41.
116. Kovacs T. Therapy of Alzheimer disease. Neuropsychopharmacol Hung 2009; 11: 27-33.
117. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009b; 61: 105-23.
118. Sanacora G, Kendell SF, Levin Y, et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007; 61: 822-5.
119. Banasr M, Chowdhury GM, Terwilliger R, et al. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry 2010; 15: 501-11.
120. Zarate CA Jr, Payne JL, Quiroz J, et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004; 161: 171-4.
121. Kotermanski SE, Johnson JW. Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine. J Neurosci 2009; 29: 2774-9.
122. Holemans S, De Paermentier F, Horton RW, Crompton MR, Katona CL, Maloteaux JM. NMDA glutamatergic receptors, labelled with [3H]MK-801, in brain samples from drug-free depressed suicides. Brain Res 1993; 616: 138-43.
123. Nowak G, Ordway GA, Paul IA. Alterations in the N-methyl-dasptartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res 1995; 675: 157-64.
124. Berk M, Plein H, Belsham B. The specificity of platelet glutamate receptor supersensitivity in psychotic disorders. Life Sci 2000; 66: 2427-32.
125. Choudary PV, Molnar M, Evans SJ, et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci U S A 2005; 102: 15653-8.
126. Feyissa AM, Chandran A, Stockmeier CA, Karolewicz B. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 70-5.
127. Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009; 66: 522-6.
128. Murrough JW, Perez AM, Pillemer S, et al. Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression. Biol Psychiatry 2012 (in press).
129. Mitchell ND, Baker GB. An update on the role of glutamate in the pathophysiology of depression. Acta Psychiatr Scand 2010; 122: 192-210.
130. Liebrenz M, Borgeat A, Leisinger R, Stohler R. Intravenous ketamine therapy in a patient with a treatment-resistant major depression. Swiss Med Wkly 2007; 137: 234-6.
131. Liebrenz M, Stohler R, Borgeat A. Repeated intravenous ketamine therapy in a patient with treatment-resistant major depression. World J Biol Psychiatry 2009; 10: 640-3.
132. Fagiolini A, Kupfer DJ. Is treatment-resistant depression a unique subtype of depression? Biol Psychiatry 2003; 53: 640-8.
133. Braun I, Genius J, Grunze H, Bender A, Möller HJ, Rujescu D. Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism. Schizophr Res 2007; 97: 254-63.
134. Gilmour G, Pioli EY, Dix SL, et al. Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for "NMDA antagonist modelling" of schizophrenia. Psychopharmacology (Berl) 2009; 205: 203-16.
135. Stuchlík A, Petrásek T, Vales K. Effect of alpha(1)-adrenergic antagonist prazosin on behavioral alterations induced by MK-801 in a spatial memory task in Long-Evans rats. Physiol Res 2009; 58: 733-40.
136. Seillier A, Giuffrida A. Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801. Behav Brain Res 2009; 204: 410-5.
137. Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995; 13: 9-19.
138. Bubenikova-Valesova V, Svoboda J, Horacek J, Vales K. The effect of a full agonist/antagonist of the D1 receptor on locomotor activity, sensorimotor gating and cognitive function in dizocilpinetreated rats. Int J Neuropsychopharmacol 2009; 12: 873-83.
139. Gozzi A, Crestan V, Turrini G, Clemens M, Bifone A. Antagonism at serotonin 5-HT(2A) receptors modulates functional activity of frontohippocampal circuit. Psychopharmacology (Berl) 2010; 209: 37-50.
140. Higgins GA, Enderlin M, Haman M, Fletcher PJ. The 5-HT2A receptor antagonist M100,907 attenuates motor and 'impulsivetype' behaviours produced by NMDA receptor antagonism. Psychopharmacology (Berl) 2003; 170: 309-19.
141. O'Neill MF, Heron-Maxwell CL, Shaw G. 5-HT2 receptor antagonism reduces hyperactivity induced by amphetamine, cocaine, and MK-801 but not D1 agonist C-APB. Pharmacol Biochem Behav 1999; 63: 237-43.
142. Werner FM, Coveñas R. Classical neurotransmitters and neuropeptides involved in major depression: a review. Int J Neurosci 2010; 120: 455-70.
143. Peng L, Li B, Du T, Wang F, Hertz L. Does conventional antibipolar and antidepressant drug therapy reduce NMDA-mediated neuronal excitation by downregulating astrocytic GluK2 function? Pharmacol Biochem Behav 2012; 100: 712-25.
144. [No authors listed]. NR2B antagonist pursued for treatmentresistant depression. Nat Rev Drug Discov 2009; 8(5): 349.
145. Rotzinger S, Lovejoy DA, Tan LA. Behavioral effects of neuropeptides in rodent models of depression and anxiety. Peptides 2010; 31: 736-56.
146. Poleszak E, Wlać P, Szewczyk B, et al. A complex interaction between glycine/NMDA receptors and serotonergic/noradrenergic antidepressants in the forced swim test in mice. J Neural Transm 2011; 118: 1535-46.
147. Muehlmann AM, Devine DP. Glutamate-mediated neuroplasticity in an animal model of self-injurious behaviour. Behav Brain Res 2008; 189: 32-40.
148. Mathews DC, Henter ID, Zarate CA. Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs 2012; 72: 1313-33.
149. Mony L, Kew JN, Gunthorpe MJ, Paoletti P. Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br J Pharmacol 2009; 157: 1301-17.
150. Marsden WN. Stressor-induced NMDAR dysfunction as a unifying hypothesis for the aetiology, pathogenesis and comorbidity of clinical depression. Med Hypotheses 2011; 77: 508-28.
151. Murrough JW, Charney DS. Is There Anything Really Novel on the Antidepressant Horizon? Curr Psychiatry Rep 2012 (in press).